A Phase 1/2 interventional study of Nivolumab and Trametinib in Colorectal Cancer, Colorectal Tumors and Colorectal Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 47 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing nivolumab in Colorectal Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. Nivolumab · Colorectal Neoplasms.
Among the 38 studies testing nivolumab in Colorectal Neoplasms, this one is the 5th largest by enrollment, is one of 4 that started in 2018, is one of 5 in phase 1/2, and was the 7th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 38 studies testing nivolumab in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in Italy
Ages 18+
GERCOR - Multidisciplinary Oncology Cooperative Group · Sites in France
Ages 18+
Blokhin's Russian Cancer Research Center · Sites in Russia
Ages 18+
Fred Hutchinson Cancer Center · Sites in Uganda
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 29 · Phase 3 4
First in 2006; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 325 is above the median of 76 across 4,802 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 49 across the 38 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 38 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
29 studies in Colorectal Neoplasms by Bristol-Myers Squibb: 4 open now, 9 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2018, is one of 10 in phase 1/2, and was the 13th registered.
Bristol-Myers Squibb’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing nivolumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04730544GERCOR - Multidisciplinary Oncology Cooperative GroupTwo Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | 2027-04 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies testing nivolumab in Colorectal Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Drug: Trametinib
Biological: Nivolumab · Drug: Trametinib · Biological: Ipilimumab
Biological: Nivolumab · Drug: Trametinib · Biological: Ipilimumab
Biological: Nivolumab · Drug: Trametinib · Biological: Ipilimumab
Drug: Regorafenib
Biological: Nivolumab · Drug: Trametinib · Biological: Ipilimumab
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Mekinist
Specified dose on specified days
Also known as: Yervoy, BMS-734016
Specified dose on specified days
Dose Limiting Toxicities in Part 1 and Part 1A
Dose Limiting Toxicities are defined as adverse events have to be at least possibly related to study treatment, and not to disease progression, be clinically relevant and a clinically relevant shift from baseline.
Time frame: 4 weeks for Doublet Reginmen and 8 weeks for triplet Regimen
Safety Related Events in Part 1 and Part 1 A
Safety-related events in clinical trials include Adverse Events (AEs), Serious Adverse Events (SAEs), and deaths. An AE is any new or worsening medical issue in a participant receiving the study drug, regardless of its relation to the drug. This includes abnormal lab results, symptoms, or diseases. An SAE is a more severe AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, involves a birth defect, or is deemed medically important-potentially jeopardizing the participant or requiring intervention, even if not immediately life-threatening. These definitions help ensure consistent reporting and evaluation of safety during clinical studies.
Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)
Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Thyroid Tests
Number of participants with clinical laboratory abnormalities in specific thyroid tests
Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)
Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Liver Tests
Number of participants with clinical laboratory abnormalities in specific liver tests.
Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)
Overal Response Rate in Part 1B and Part 2
ORR is defined as the proportion of all treated participants whose BOR is either confirmed complete response (CR) or confirmed partial response (PR).
Time frame: Approximately up to 30 Months
Objective Response Rate in Part 1 and Part 1A
ORR is defined as the proportion of all treated participants whose BOR is either confirmed complete response (CR) or confirmed partial response (PR).
Time frame: From the first dosing date and the date of the initial objectively documented tumor progression or subsequent therapy date (Approximately up to 21 Months)
Disease Control Rate in Part 1 and Part 1A
The disease control rate (DCR) is defined as the percentage of participants whose BOR is either confirmed CR or confirmed PR or stable disease (SD)
Time frame: From the first dosing date and the date of the initial objectively documented tumor progression or subsequent therapy date (Approximately up to 21 Months)
Duration of Response in Part 1 and Part 1A
DOR for a participant with a BOR of confirmed CR or PR, is defined as the time between the date of first confirmed response and the date of the first objectively documented tumor progression per RECIST 1.1 or death, whichever occurs first.
Time frame: Approximately up to 20 Months
Time to Response in Part 1 and Part 1A
Time to response (TTR) is defined for participants who had a confirmed CR or PR as the time from the first dosing date to the date of first documented CR or PR per RECIST 1.1.
Time frame: From the first dosing date to the date of first documented CR or PR per RECIST 1.1. (Approximately on average 10 months)
Progression Free Survival in Part 1 and Part 1A
PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression per RECIST 1.1 (ie, radiologic) or death due to any cause, whichever occurs first.
Time frame: from the first dosing date to the date of first objectively documented disease progression or death, whichever occurs first (Approximately up to 21 months)
Overall Survival in Part 1 and Part 1A
OS for a participant is defined as the time from the first dosing date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.
Time frame: Approximately up to 69 Months
Safety Related Events in Part 1B and Part 2
Safety-related events in clinical trials include Adverse Events (AEs), Serious Adverse Events (SAEs), and deaths. An AE is any new or worsening medical issue in a participant receiving the study drug, regardless of its relation to the drug. This includes abnormal lab results, symptoms, or diseases. An SAE is a more severe AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, involves a birth defect, or is deemed medically important-potentially jeopardizing the participant or requiring intervention, even if not immediately life-threatening. These definitions help ensure consistent reporting and evaluation of safety during clinical studies.
Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)
Clinical Laboratory Abnormalities in Part 1B and Part 2: Specific Thyroid Tests
Number of participants with clinical laboratory abnormalities in specific thyroid tests
Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)
Clinical Laboratory Abnormalities in Part 1B and Part 2: Specific Liver Tests
Number of participants with clinical laboratory abnormalities in specific liver tests.
Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)
| Milestone | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B | Part 2 Treatment 1 | Part 2 Treatment 2 | Part 1B |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 6 | 7 | 3 | 3 | 7 | 124 | 61 | 82 |
| Completed | 3 | 3 | 6 | 7 | 3 | 3 | 7 | 121 | 57 | 82 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 0 |
| Withdrew: Subject withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 |
| Withdrew: Not reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Milestone | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B | Part 2 Treatment 1 | Part 2 Treatment 2 | Part 1B |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 6 | 7 | 3 | 3 | 7 | 121 | 57 | 82 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Not completed | 3 | 3 | 6 | 7 | 3 | 3 | 7 | 120 | 57 | 81 |
| Withdrew: Disease progression | 3 | 2 | 5 | 3 | 3 | 3 | 6 | 106 | 48 | 59 |
| Withdrew: Study drug toxicity | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 2 | 16 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 0 |
| Withdrew: Subject request to discontinue study treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Subject withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: No longer meets study criteria | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 1 |
Dose Limiting Toxicities are defined as adverse events have to be at least possibly related to study treatment, and not to disease progression, be clinically relevant and a clinically relevant shift from baseline.
| Participants | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| Dose Limiting Toxicities in Part 1 and Part 1A | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
Safety-related events in clinical trials include Adverse Events (AEs), Serious Adverse Events (SAEs), and deaths. An AE is any new or worsening medical issue in a participant receiving the study drug, regardless of its relation to the drug. This includes abnormal lab results, symptoms, or diseases. An SAE is a more severe AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, involves a birth defect, or is deemed medically important-potentially jeopardizing the participant or requiring intervention, even if not immediately life-threatening. These definitions help ensure consistent reporting and evaluation of safety during clinical studies.
| Participants | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| Adverse Events (AEs) | 3 | 3 | 6 | 7 | 3 | 3 | 7 |
| Drug-Related AEs | 3 | 3 | 6 | 7 | 3 | 3 | 7 |
| Serious Adverse Events (SAEs) | 2 | 0 | 4 | 3 | 0 | 2 | 3 |
| Drug-Related SAEs | 0 | 0 | 2 | 3 | 0 | 1 | 1 |
| Deaths | 2 | 2 | 6 | 3 | 2 | 3 | 5 |
Number of participants with clinical laboratory abnormalities in specific thyroid tests
| Participants | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| TSH > ULN | 2 | 1 | 1 | 3 | 1 | 3 | 2 |
| TSH > ULN WITH TSH ≤ ULN AT BASELINE | 2 | 1 | 1 | 0 | 0 | 2 | 2 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 2 | 1 | 1 | 1 | 0 | 1 | 1 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN | 0 | 0 | 0 | 2 | 1 | 2 | 1 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TSH < LLN | 2 | 0 | 2 | 2 | 2 | 1 | 2 |
| TSH <LLN WITH TSH ≥ LLN AT BASELINE | 1 | 0 | 2 | 1 | 2 | 1 | 2 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 2 | 0 | 1 | 1 | 0 | 1 | 2 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES ≤ ULN | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Number of participants with clinical laboratory abnormalities in specific liver tests.
| Participants | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| ALT OR AST > 3XULN | 0 | 0 | 2 | 1 | 1 | 0 | 2 |
| ALT OR AST> 5XULN | 0 | 0 | 2 | 1 | 1 | 0 | 2 |
| ALT OR AST> 10XULN | 0 | 0 | 2 | 1 | 0 | 0 | 2 |
| ALT OR AST > 20XULN | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| TOTAL BILIRUBIN > 2XULN | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
ORR is defined as the proportion of all treated participants whose BOR is either confirmed complete response (CR) or confirmed partial response (PR).
| Percentage of Participants | Part 1B | Part 2 Treatment 1 | Part 2 Treatment 2 |
|---|---|---|---|
| Overal Response Rate in Part 1B and Part 2 | 9.8 (4.3 to 18.3) | 1.6 (0.2 to 5.7) | 1.6 (0.0 to 8.8) |
ORR is defined as the proportion of all treated participants whose BOR is either confirmed complete response (CR) or confirmed partial response (PR).
| Percentage of Participants | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| Objective Response Rate in Part 1 and Part 1A | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 45.9) | 28.6 (3.7 to 71.0) | 33.3 (0.8 to 90.6) | 0 (0.0 to 70.8) | 0 (0.0 to 41.0) |
The disease control rate (DCR) is defined as the percentage of participants whose BOR is either confirmed CR or confirmed PR or stable disease (SD)
| Percentage of Participants | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| Disease Control Rate in Part 1 and Part 1A | 66.7 (9.4 to 99.2) | 33.3 (0.8 to 90.6) | 50.0 (11.8 to 88.2) | 57.1 (18.4 to 90.1) | 33.3 (0.8 to 90.6) | 66.7 (9.4 to 99.2) | 28.6 (3.7 to 71.0) |
DOR for a participant with a BOR of confirmed CR or PR, is defined as the time between the date of first confirmed response and the date of the first objectively documented tumor progression per RECIST 1.1 or death, whichever occurs first.
| Months | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| Duration of Response in Part 1 and Part 1A | — | — | — | 9.46 (NA to NA) | 19.42 (NA to NA) | — | — |
Time to response (TTR) is defined for participants who had a confirmed CR or PR as the time from the first dosing date to the date of first documented CR or PR per RECIST 1.1.
| Months | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| Time to Response in Part 1 and Part 1A | — | — | — | 5.63 (1.8 to 9.5) | 1.54 (1.54 to 1.54) | — | — |
PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression per RECIST 1.1 (ie, radiologic) or death due to any cause, whichever occurs first.
| Months | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| Progression Free Survival in Part 1 and Part 1A | 3.58 (1.84 to NA) | 1.91 (1.74 to NA) | 2.66 (0.79 to NA) | 7.36 (1.84 to NA) | 1.74 (1.74 to NA) | 4.14 (1.84 to NA) | 1.81 (0.92 to NA) |
OS for a participant is defined as the time from the first dosing date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.
| Months | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B |
|---|---|---|---|---|---|---|---|
| Overall Survival in Part 1 and Part 1A | 8.99 (8.80 to NA) | 18.50 (17.45 to NA) | 9.61 (0.89 to NA) | 42.09 (11.60 to NA) | 19.02 (8.80 to NA) | 11.33 (10.51 to NA) | 36.24 (2.23 to NA) |
Safety-related events in clinical trials include Adverse Events (AEs), Serious Adverse Events (SAEs), and deaths. An AE is any new or worsening medical issue in a participant receiving the study drug, regardless of its relation to the drug. This includes abnormal lab results, symptoms, or diseases. An SAE is a more severe AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, involves a birth defect, or is deemed medically important-potentially jeopardizing the participant or requiring intervention, even if not immediately life-threatening. These definitions help ensure consistent reporting and evaluation of safety during clinical studies.
| Participants | Part 1B | Part 2 Treatment 1 | Part 2 Treatment 2 |
|---|---|---|---|
| Adverse Events (AEs) | 82 | 121 | 57 |
| Drug-Related AEs | 80 | 116 | 52 |
| Serious Adverse Events (SAEs) | 36 | 56 | 19 |
| Drug-Related SAEs | 20 | 21 | 3 |
| Deaths | 49 | 106 | 53 |
Number of participants with clinical laboratory abnormalities in specific thyroid tests
| Participants | Part 1B | Part 2 Treatment 1 | Part 2 Treatment 2 |
|---|---|---|---|
| TSH > ULN | 13 | 31 | 21 |
| TSH > ULN WITH TSH ≤ ULN AT BASELINE | 9 | 18 | 16 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 9 | 14 | 3 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN | 3 | 13 | 14 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 1 | 4 | 4 |
| TSH < LLN | 14 | 24 | 0 |
| TSH <LLN WITH TSH ≥ LLN AT BASELINE | 11 | 21 | 0 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 5 | 12 | 0 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES ≤ ULN | 8 | 7 | 0 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 1 | 5 | 0 |
Number of participants with clinical laboratory abnormalities in specific liver tests.
| Participants | Part 1B | Part 2 Treatment 1 | Part 2 Treatment 2 |
|---|---|---|---|
| ALT OR AST > 3XULN | 18 | 38 | 11 |
| ALT OR AST> 5XULN | 8 | 19 | 8 |
| ALT OR AST> 10XULN | 1 | 5 | 4 |
| ALT OR AST > 20XULN | 0 | 3 | 2 |
| TOTAL BILIRUBIN > 2XULN | 3 | 9 | 12 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 2 | 6 | 7 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 2 | 7 | 7 |
Collected over Part 1: Approximately 5.5 Months Part 1A: Approximately 6.5 Months Part 1B and 2: Approximately 6.8 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Cohort 1 | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1 Cohort 1B | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Part 1 Cohort 1D | 6/6 (100%) | 5/6 (83.3%) | 6/6 (100%) |
| Part 1A Cohort 2 | 3/7 (42.9%) | 3/7 (42.9%) | 7/7 (100%) |
| Part 1A Cohort 2A | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Part 1A Cohort 3 | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1A Cohort 3B | 5/7 (71.4%) | 3/7 (42.9%) | 7/7 (100%) |
| Part 1B | 49/82 (59.8%) | 42/82 (51.2%) | 82/82 (100%) |
| Part 2 Treatment 1 | 108/124 (87.1%) | 79/121 (65.3%) | 121/121 (100%) |
| Part 2 Treatment 2 | 55/61 (90.2%) | 33/57 (57.9%) | 55/57 (96.5%) |
| Event | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B | Part 1B | Part 2 Treatment 1 | Part 2 Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 0/6 | 0/7 | 0/3 | 0/3 | 0/7 | 11/82 | 42/121 | 21/57 |
| HypothyroidismEndocrine disorders | 0/3 | 0/3 | 0/6 | 0/7 | 0/3 | 1/3 | 0/7 | 0/82 | 0/121 | 0/57 |
| Abdominal distensionGastrointestinal disorders | 1/3 | 0/3 | 0/6 | 0/7 | 0/3 | 0/3 | 0/7 | 0/82 | 0/121 | 0/57 |
| Large intestinal obstructionGastrointestinal disorders | 0/3 | 0/3 | 0/6 | 0/7 | 0/3 | 1/3 | 0/7 | 0/82 | 0/121 | 0/57 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/3 | 0/3 | 0/6 | 0/7 | 0/3 | 1/3 | 0/7 | 0/82 | 1/121 | 0/57 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/3 | 0/3 | 0/6 | 0/7 | 0/3 | 0/3 | 0/7 | 0/82 | 0/121 | 0/57 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/6 | 0/7 | 0/3 | 1/3 | 0/7 | 0/82 | 2/121 | 0/57 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 0/6 | 2/7 | 0/3 | 0/3 | 0/7 | 5/82 | 7/121 | 2/57 |
| Atrial fibrillationCardiac disorders | 0/3 | 0/3 | 1/6 | 0/7 | 0/3 | 0/3 | 0/7 | 0/82 | 0/121 | 0/57 |
| ColitisGastrointestinal disorders | 0/3 | 0/3 | 1/6 | 0/7 | 0/3 | 0/3 | 0/7 | 1/82 | 2/121 | 0/57 |
| Event | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B | Part 1B | Part 2 Treatment 1 | Part 2 Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/3 | 2/3 | 4/6 | 6/7 | 2/3 | 2/3 | 4/7 | 45/82 | 52/121 | 22/57 |
| NauseaGastrointestinal disorders | 3/3 | 0/3 | 2/6 | 5/7 | 1/3 | 2/3 | 5/7 | 26/82 | 55/121 | 9/57 |
| FatigueGeneral disorders | 3/3 | 1/3 | 4/6 | 7/7 | 3/3 | 1/3 | 6/7 | 33/82 | 51/121 | 22/57 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 2/3 | 3/3 | 5/6 | 4/7 | 3/3 | 3/3 | 6/7 | 20/82 | 39/121 | 2/57 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 0/3 | 3/6 | 4/7 | 1/3 | 2/3 | 4/7 | 18/82 | 36/121 | 12/57 |
| Abdominal distensionGastrointestinal disorders | 1/3 | 0/3 | 1/6 | 0/7 | 2/3 | 1/3 | 1/7 | 2/82 | 4/121 | 0/57 |
| Abdominal painGastrointestinal disorders | 1/3 | 0/3 | 1/6 | 1/7 | 2/3 | 1/3 | 1/7 | 18/82 | 17/121 | 9/57 |
| Dry mouthGastrointestinal disorders | 1/3 | 0/3 | 0/6 | 1/7 | 0/3 | 2/3 | 0/7 | 6/82 | 7/121 | 5/57 |
| VomitingGastrointestinal disorders | 1/3 | 0/3 | 2/6 | 2/7 | 2/3 | 2/3 | 2/7 | 17/82 | 36/121 | 5/57 |
| ChillsGeneral disorders | 2/3 | 0/3 | 0/6 | 2/7 | 0/3 | 1/3 | 1/7 | 4/82 | 9/121 | 1/57 |
| Age, Categorical(Participants) | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B | Part 2 Treatment 1 | Part 2 Treatment 2 | Part 1B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 2 | 3 | 5 | 6 | 2 | 3 | 6 | 89 | 47 | 60 | 223 |
| Between 18 and 65 years | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 35 | 14 | 22 | 76 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B | Part 2 Treatment 1 | Part 2 Treatment 2 | Part 1B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 0 | 4 | 2 | 1 | 3 | 48 | 30 | 37 | 129 |
| Male | 0 | 2 | 6 | 3 | 1 | 2 | 4 | 76 | 31 | 45 | 170 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B | Part 2 Treatment 1 | Part 2 Treatment 2 | Part 1B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 10 | 6 | 7 | 25 |
| Not Hispanic or Latino | 3 | 3 | 6 | 6 | 3 | 2 | 7 | 55 | 27 | 51 | 163 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 59 | 28 | 24 | 111 |
| Race (NIH/OMB)(Participants) | Part 1 Cohort 1 | Part 1 Cohort 1B | Part 1 Cohort 1D | Part 1A Cohort 2 | Part 1A Cohort 2A | Part 1A Cohort 3 | Part 1A Cohort 3B | Part 2 Treatment 1 | Part 2 Treatment 2 | Part 1B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 5 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| White | 3 | 3 | 4 | 6 | 3 | 2 | 6 | 119 | 58 | 74 | 278 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Nov 2024, 81 months.
Results were first posted in Dec 2025, 1 year after primary completion.
Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's 81 months is above that.
Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Trametinib · Ipilimumab · Regorafenib